Welcome to
the M.A.G.I.C. CLINIC
At M.A.G.I.C. Canada, We Care for People with Rare Metabolic and Genetic Diseases
Important Location Information
Location: #102, 6715 8 Street NE, Calgary, AB T2E 7H7
We’re in the Deerfoot South Atria in Calgary. Please use the main entrance on the east side of the building. Once inside, our clinic is the first door on your right.
Parking:
-
2 spots are located between the North and South buildings (facing south).
-
2 spots are in the south parking lot (facing east toward 8 Street).
Who we are
M.A.G.I.C. stands for Metabolics and Genetics in Canada. We are a medical clinic that specializes in looking after patients (children and adults) with rare diseases that are due to changes in their DNA. Things like Lysosomal Storage Diseases (Fabry disease, Gaucher disease, Pompe disease to name a few), Mitochondrial Diseases, and overall more than 7,000 known different genetic diseases.
OUR FOCUS
We use a modern approach to diagnose and treat rare diseases with a team that cares about how well you do
OUR APPROACH
We have technologies that can give you results on genetic testing in record time. That gives you fast access to Whole Exome Sequencing, Whole Genome Sequencing, and our unique Mitochondrial Genome Sequencing
TREATMENTS
We look at finding those special medications that can make a difference. We have the largest clinic in Alberta for patients with lysosomal diseases needing enzyme therapies or spinal injection therapies
Our Clinical Trials Unit is dedicated to providing access to research therapies for rare metabolic and genetic diseases
We provide Non-Invasive Prenatal Screening for Trisomy 21 and other conditions with only one tube of blood
Hereditary CANCER Testing
We offer genetic counselling and testing for hereditary cancers.
Learn About our Clinical Trials
Below is a list of our actively recruiting clinical trials. Want to learn more? View our clinical trials page to learn more about active, past, and completed clinical trials.
PKU: JNT517-301
Short Summary:
This Phase 3 clinical trial is evaluating the safety and effectiveness of an investigational treatment called repinatrabit (JNT-517) for adults with PKU (Phenylketonuria). Approximately 120 participants will take part in the study, which includes a screening period of up to 35 days to confirm eligibility and dietary stability, followed by up to 14 months of study participation.
Who May Qualify:
• Adults 18 years of age or older
• Individuals diagnosed with Phenylketonuria (PKU)
• Body weight greater than 40 kg
• Not currently receiving pegvaliase treatment or have stopped pegvaliase at least 4 weeks prio
Links & Contacts:
- Recruitment Contact: research@magiccalgary.ca
- VIPeR Registry Link
- ClinicalTrials.gov Link
NPC GM1 GM2: AZ-3102 (AZA-001-301)
Short Summary:
This Phase 3 clinical trial is evaluating the safety and effectiveness of an investigational oral medication called nizubaglustat (AZ-3102) for children and young people living with certain rare genetic conditions, including Niemann-Pick type C disease, GM1 gangliosidosis, and GM2 gangliosidosis. The study will take place over approximately 18 months and will compare nizubaglustat to a placebo to better understand how the treatment may help manage these conditions.
Who May Qualify:
You or your child may qualify for this study if you:
- Are 4 years of age or older
- Have a confirmed diagnosis of Niemann-Pick type C (NPC), GM1 gangliosidosis, or GM2 gangliosidosis
- Are unable or unwilling to take miglustat
- Have genetic testing results confirming the diagnosis through disease-causing genetic variants identified by the study team
Links & Contacts:
- Recruitment Contact: research@magiccalgary.ca
- VIPeR Registry Link
- ClinicalTrials.gov Link
PKU: Palynziq Registry (Biomarin 165-504)
Learn more about one of our latest studies Pegvaliase: a global, multicenter study to assess maternal, fetal and infant outcomes of exposure to Palynziq® (pegvaliase) during pregnancy and breastfeeding. Read more about the study here.
Noonan Syndrome: BMN111-211
Short Summary:
This Phase 2 clinical trial is studying an investigational medication called vosoritide in children with Noonan syndrome who have experienced limited growth during or after treatment with human growth hormone (hGH). Researchers are evaluating the safety of different dosing options and how well the medication may help support growth, including its potential impact on final adult height.
Who May Qualify:
Your child may qualify for this study if they:
- Are between 3 and 11 years old (girls) or 3 and 12 years old (boys)
- Have a confirmed diagnosis of Noonan syndrome
- Are shorter than expected for their age and sex and have experienced limited growth despite current or previous growth hormone treatment
- Have not yet started puberty at the time of study enrollment
Links & Contacts:
- Recruitment Contact: research@magiccalgary.ca
- VIPeR Registry Link
- ClinicalTrials.gov Link
Sanofi Registries, Fabry, Gaucher, Pompe
Fabry: CFDI Registry
MEET DR. ANEAL KHAN
Pediatrician and Medical Geneticist
MSc (Nutrition), MD, FRCPC (Pediatrics), FCCMG (Medical Genetics)
Since 2021, Dr Khan has focused on improving access and reducing wait times by establishing a community-based clinic: the M.A.G.I.C. Clinic in Calgary.
He was the first physician in the world to treat Fabry disease and Gaucher disease using Gene Therapy, the first in Canada to use Liver Cell Transplant and Gene Therapy to treat Urea Cycle Diseases and is experienced in using research drugs injected directly into the spine.
Learning Videos
These videos can provide you with an idea of how genetic sequencing looks and what it can be used for.
Some content you are viewing is external content. Neither M.A.G.I.C. Clinic, Dr. Aneal Khan, nor their affiliates have control over these videos and are not responsible for their content.
Discovery DNA Lab Tour
How to sequence the human genome
Whole Genome Sequencing
Detecting rare metabolic disease
Want to Learn More?
Reach a Team that cares about you
Get In Touch: